HRP20240192T1 - Medicinski flaster sa sporim otpuštanjem - Google Patents
Medicinski flaster sa sporim otpuštanjem Download PDFInfo
- Publication number
- HRP20240192T1 HRP20240192T1 HRP20240192TT HRP20240192T HRP20240192T1 HR P20240192 T1 HRP20240192 T1 HR P20240192T1 HR P20240192T T HRP20240192T T HR P20240192TT HR P20240192 T HRP20240192 T HR P20240192T HR P20240192 T1 HRP20240192 T1 HR P20240192T1
- Authority
- HR
- Croatia
- Prior art keywords
- matrix
- relation
- dry mass
- mass
- psa
- Prior art date
Links
- 239000011505 plaster Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 claims 38
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 16
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 8
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 6
- 229960001193 diclofenac sodium Drugs 0.000 claims 6
- 230000007935 neutral effect Effects 0.000 claims 6
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 6
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims 6
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 5
- 239000006185 dispersion Substances 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 230000001681 protective effect Effects 0.000 claims 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 239000004745 nonwoven fabric Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Finger-Pressure Massage (AREA)
Claims (11)
1. Medicinski flaster koji sadrži
• osnovni sloj,
• „na pritisak osjetljiv adhezivni“ (PSA) matriks,
• zaštitni prekrivni sloj,
pri čemu PSA matriks sadrži ili se sastoji od:
• neutralnog kopolimera na bazi etil akrilata i metil metakrilata u odnosu 2:1, u koncentraciji u opsegu od 40 do 49% suhe mase u odnosu na suhu masu matriksa;
• sredstva za plastifikaciju odabranog od estara limunske kiseline, u koncentraciji u opsegu od 40 do 49 mas% u odnosu na suhu masu matriksa;
• butilhidroksianizola (BHA) u koncentraciji u opsegu od 0.10 do 0.20 mas% u odnosu na suhu masu matriksa;
pri čemu je u navedenom PSA matriksu disperziran
• aktivni sastojak, koji je diklofenak natrij, u koncentraciji u opsegu od 1 do 20 mas% u odnosu na suhu masu matriksa.
2. Medicinski flaster prema patentnom zahtjevu 1, pri čemu su esteri limunske kiseline odabrani od trietil citrata, acetil trietil citrata, acetil tributil citrata, tributil citrata, poželjno estar je tributil citrat.
3. Medicinski flaster prema jednom ili više prethodnih patentnih zahtjeva, pri čemu PSA matriks sadrži ili se sastoji od:
• neutralnog kopolimera na bazi etil akrilata i metil metakrilata u odnosu 2:1 u vodenoj disperziji sa 40 mas%, u koncentraciji u rasponu od 45 do 48% suhe mase u odnosu na suhu masu matriksa;
• sredstva za plastifikaciju koje je tributil citrat, u koncentraciji u rasponu od 45 do 48 mas% u odnosu na suhu masu matriksa;
• BHA u koncentraciji u rasponu od 0.13 do 0.18 mas% u odnosu na suhu masu matriksa;
pri čemu je diklofenak natrij disperziran u navedenom PSA matriksu, u koncentraciji u rasponu od 5 do 10 mas% u odnosu na suhu masu matriksa.
4. Medicinski flaster prema jednom ili više prethodnih patentnih zahtjeva, pri čemu PSA matriks sadrži ili se sastoji od:
• neutralnog kopolimera na bazi etil akrilata i metil metakrilata u odnosu 2:1 u vodenoj disperziji sa 40 mas%, u koncentraciji jednakoj 46.3% suhe mase u odnosu na suhu masu matriksa;
• tributil citrata, u koncentraciji jednakoj 46.3 mas% u odnosu na suhu masu matriksa;
• BHA u koncentraciji od 0.15 mas% u odnosu na suhu masu matriksa;
pri čemu je diklofenak natrij disperziran u spomenutom PSA matriksu, u koncentraciji jednakoj 7.25 mas% u odnosu na suhu masu matriksa.
5. Medicinski flaster prema jednom ili više prethodnih patentnih zahtjeva, pri čemu se osnovni sloj sastoji od neperforirane 100% poliesterske netkane tkanine.
6. Medicinski flaster prema jednom ili više prethodnih patentnih zahtjeva, pri čemu je zaštitni prekrivni sloj zaštitni list od monosilikonskog papira.
7. Medicinski flaster prema jednom ili više prethodnih patentnih zahtjeva, za primjenu u liječenju jednom dnevno bolnih i inflamatornih stanja koja utječu na mišićno-skeletni sistem, kao što je na primjer osteoartritis, kao i traume kao što su uganuća, puknuće mišića, modrice sa neoštećenom kožom.
8. „Na pritisak osjetljiv adhezivni“ (PSA) matriks koji sadrži ili se sastoji od:
• neutralnog kopolimera na bazi etil akrilata i metil metakrilata u odnosu 2:1, u koncentraciji u rasponu od 40 do 49% suhe mase u odnosu na suhu masu matriksa;
• sredstva za plastifikaciju odabranog od estara limunske kiseline, u koncentraciji u rasponu od 40 do 49 mas% u odnosu na suhu masu matriksa;
• butilhidroksianizola (BHA) u koncentraciji u rasponu od 0.10 do 0.20 mas% u odnosu na suhu masu matriksa;
pri čemu je u spomenutom PSA matriksu disperziran
• aktivni sastojak, a to je diklofenak natrij, u koncentraciji u rasponu od 1 do 20 mas% u odnosu na suhu masu matriksa.
9. „Na pritisak osjetljiv adhezivni“ (PSA) matriks prema patentnom zahtjevu 8, pri čemu su esteri izabrani od trietil citrata, acetil trietil citrata, acetil tributil citrata, tributil citrata, poželjno estar je tributil citrat.
10. „Na pritisak osetljiv adhezivni“ (PSA) matriks prema patentnom zahtjevu 8, koji sadrži ili se sastoji od:
• neutralnog kopolimera na bazi etil akrilata i metil metakrilata u odnosu 2:1 u vodenoj disperziji sa 40 mas%, u koncentraciji u rasponu od 45 do 48% suhe mase u odnosu na suhu masu matriksa;
• sredstva za plastifikaciju koje je tributil citrat, u koncentraciji u rasponu od 45 do 48 mas% u odnosu na suhu masu matriksa;
• BHA u koncentraciji u rasponu od 0.13 do 0.18 mas% u odnosu na suhu masu matriksa;
pri čemu je diklofenak natrij disperziran u spomenutom PSA matriksu, u koncentraciji u rasponu od 5 do 10 mas% u odnosu na suhu masu matriksa.
11. „Na pritisak osjetljiv adhezivni“ (PSA) matriks prema patentnom zahtjevu 8, koji sadrži ili se sastoji od:
• neutralnog kopolimera na bazi etil akrilata i metil metakrilata u odnosu 2:1 u vodenoj disperziji pri 40 mas%, u koncentraciji jednakoj 46.3% suhe mase u odnosu na suhu masu matriksa;
• tributil citrata, u koncentraciji jednakoj 46.3 mas% u odnosu na suhu masu matriksa;
• BHA u koncentraciji jednakoj 0.15 mas% u odnosu na suhu masu matriksa;
pri čemu je diklofenak natrij disperziran u spomenutom PSA matriksu, u koncentraciji jednakoj 7.25 mas% u odnosu na suhu masu matriksa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000011686A IT202000011686A1 (it) | 2020-05-20 | 2020-05-20 | Cerotto medicato a lento rilascio |
EP21726205.4A EP4153151B1 (en) | 2020-05-20 | 2021-05-18 | Slow-release medical plaster |
PCT/IB2021/054261 WO2021234562A1 (en) | 2020-05-20 | 2021-05-18 | Slow-release medical plaster |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240192T1 true HRP20240192T1 (hr) | 2024-05-10 |
Family
ID=71994907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240192TT HRP20240192T1 (hr) | 2020-05-20 | 2021-05-18 | Medicinski flaster sa sporim otpuštanjem |
Country Status (35)
Country | Link |
---|---|
US (1) | US20230190668A1 (hr) |
EP (1) | EP4153151B1 (hr) |
KR (1) | KR20230013033A (hr) |
CN (1) | CN115666537A (hr) |
AR (1) | AR122136A1 (hr) |
AT (1) | AT525409A3 (hr) |
BE (1) | BE1028251B1 (hr) |
CA (1) | CA3178964A1 (hr) |
CH (1) | CH718822B1 (hr) |
CZ (1) | CZ2022461A3 (hr) |
DE (1) | DE112021002871T5 (hr) |
DK (2) | DK4153151T3 (hr) |
EE (1) | EE05862B1 (hr) |
ES (1) | ES2936185R1 (hr) |
FI (1) | FI4153151T3 (hr) |
FR (1) | FR3110397A1 (hr) |
GB (1) | GB2610106A (hr) |
GR (1) | GR1010304B (hr) |
HR (1) | HRP20240192T1 (hr) |
HU (1) | HUP2200459A2 (hr) |
IE (1) | IE20210109A1 (hr) |
IT (1) | IT202000011686A1 (hr) |
LT (1) | LT4153151T (hr) |
LU (1) | LU501245B1 (hr) |
MA (1) | MA59594B1 (hr) |
MD (1) | MD4153151T2 (hr) |
NL (1) | NL2028233B1 (hr) |
PL (2) | PL442805A1 (hr) |
PT (1) | PT4153151T (hr) |
RO (1) | RO137440A2 (hr) |
RS (1) | RS65194B1 (hr) |
SI (1) | SI4153151T1 (hr) |
SK (1) | SK500562022A3 (hr) |
TR (1) | TR2021008324A2 (hr) |
WO (1) | WO2021234562A1 (hr) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09208463A (ja) * | 1996-02-07 | 1997-08-12 | Tsumura & Co | 経皮吸収性に優れた消炎鎮痛組成物 |
JP4181232B2 (ja) * | 1997-07-18 | 2008-11-12 | 帝國製薬株式会社 | ジクロフェナクナトリウム含有油性外用貼付製剤 |
JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
CN1215838C (zh) * | 2003-06-25 | 2005-08-24 | 蚌埠丰原医药科技发展有限公司 | 双氯芬酸钠贴剂及其制备方法 |
EP1807033B1 (en) * | 2004-10-08 | 2016-07-20 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
EP1877509B1 (en) | 2005-03-17 | 2011-10-12 | Pharmafilm S.R.L. | An aqueous polymeric system for pressure sensitive adhesive matrix preparation |
US20070259029A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water-dispersible patch containing an active agent for dermal delivery |
EA201390980A1 (ru) | 2010-12-29 | 2013-11-29 | Фармафилм С.Р.Л. | Лекарственный пластырь для улучшенного трансдермального проникновения диклофенака диэтиламмония |
BR112013030365A2 (pt) * | 2011-05-26 | 2016-11-29 | Novartis Ag | composições para administração percutânea de princípio ativo fisiologicamente |
WO2013191128A1 (ja) * | 2012-06-20 | 2013-12-27 | 久光製薬株式会社 | 貼付剤 |
US9962349B2 (en) | 2014-10-17 | 2018-05-08 | Fidia Farmaceutici S.P.A. | Dermal therapeutic system with high adhesivity |
-
2020
- 2020-05-20 IT IT102020000011686A patent/IT202000011686A1/it unknown
-
2021
- 2021-05-11 GR GR20210100319A patent/GR1010304B/el active IP Right Grant
- 2021-05-18 MA MA59594A patent/MA59594B1/fr unknown
- 2021-05-18 PL PL442805A patent/PL442805A1/pl unknown
- 2021-05-18 LU LU501245A patent/LU501245B1/fr active IP Right Grant
- 2021-05-18 CA CA3178964A patent/CA3178964A1/en active Pending
- 2021-05-18 EP EP21726205.4A patent/EP4153151B1/en active Active
- 2021-05-18 RO ROA202200733A patent/RO137440A2/ro unknown
- 2021-05-18 AT ATA9160/2021A patent/AT525409A3/de unknown
- 2021-05-18 DK DK21726205.4T patent/DK4153151T3/da active
- 2021-05-18 CZ CZ2022-461A patent/CZ2022461A3/cs unknown
- 2021-05-18 CH CH001380/2022A patent/CH718822B1/it not_active IP Right Cessation
- 2021-05-18 SK SK50056-2022A patent/SK500562022A3/sk unknown
- 2021-05-18 ES ES202290075A patent/ES2936185R1/es active Pending
- 2021-05-18 US US17/925,515 patent/US20230190668A1/en active Pending
- 2021-05-18 HR HRP20240192TT patent/HRP20240192T1/hr unknown
- 2021-05-18 RS RS20240130A patent/RS65194B1/sr unknown
- 2021-05-18 KR KR1020227040002A patent/KR20230013033A/ko unknown
- 2021-05-18 PT PT217262054T patent/PT4153151T/pt unknown
- 2021-05-18 DE DE112021002871.5T patent/DE112021002871T5/de active Pending
- 2021-05-18 MD MDE20230333T patent/MD4153151T2/ro unknown
- 2021-05-18 NL NL2028233A patent/NL2028233B1/en active
- 2021-05-18 GB GB2217015.3A patent/GB2610106A/en active Pending
- 2021-05-18 EE EEP202200014A patent/EE05862B1/et unknown
- 2021-05-18 FI FIEP21726205.4T patent/FI4153151T3/fi active
- 2021-05-18 SI SI202130104T patent/SI4153151T1/sl unknown
- 2021-05-18 CN CN202180036277.8A patent/CN115666537A/zh active Pending
- 2021-05-18 PL PL21726205.4T patent/PL4153151T3/pl unknown
- 2021-05-18 LT LTEPPCT/IB2021/054261T patent/LT4153151T/lt unknown
- 2021-05-18 HU HU2200459A patent/HUP2200459A2/hu unknown
- 2021-05-18 WO PCT/IB2021/054261 patent/WO2021234562A1/en active Application Filing
- 2021-05-19 IE IE20210109A patent/IE20210109A1/en unknown
- 2021-05-19 FR FR2105212A patent/FR3110397A1/fr active Pending
- 2021-05-19 TR TR2021/008324A patent/TR2021008324A2/tr unknown
- 2021-05-20 BE BE20215409A patent/BE1028251B1/fr active IP Right Grant
- 2021-05-20 AR ARP210101380A patent/AR122136A1/es unknown
-
2022
- 2022-11-14 DK DKPA202201037A patent/DK202201037A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3962684B2 (ja) | 改善された水分吸収能および接着性を有する経皮投与剤 | |
CA2542688C (en) | Adhesive preparation | |
Cilurzo et al. | Application of methyl methacrylate copolymers to the development of transdermal or loco-regional drug delivery systems | |
CA2794734A1 (en) | Transdermal delivery patch | |
PT95505B (pt) | Adesivos contendo estrogenios como substancia activa | |
JP2007511605A5 (hr) | ||
JP7257410B2 (ja) | 含水系貼付剤 | |
US20110244023A1 (en) | Transdermal delivery patch | |
JP2002537244A5 (ja) | デオキシペガニン含有の経皮治療用薬剤 | |
HRP20240192T1 (hr) | Medicinski flaster sa sporim otpuštanjem | |
JP4799783B2 (ja) | 伸縮性外用貼付剤 | |
JPS596287B2 (ja) | 医薬製剤 | |
JPS58174484A (ja) | 感圧性粘着テ−プ又はシ−ト | |
WO2014171538A1 (ja) | 貼付剤用支持体及びこれを用いた貼付剤 | |
JP4620861B2 (ja) | 貼付剤 | |
JP7219177B2 (ja) | 非水系貼付剤 | |
JP2002167335A (ja) | 肌荒れ治療用製剤及び肌荒れ治療用貼付剤 | |
JPH01101975A (ja) | 口腔粘膜用貼付剤 | |
JP2022142438A (ja) | 水分センサー機能付含水系貼付剤 | |
WO2021192366A1 (ja) | 貼付剤 | |
WO2021193874A1 (ja) | 貼付剤 | |
JP2022131753A (ja) | 非水系貼付剤 | |
JPH0912449A (ja) | 貼付剤 | |
JPS62283921A (ja) | 局部用粘着性医薬部材 | |
JPH11199518A (ja) | 温感剤組成物及び皮膚外用剤 |